Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer

Next Previous
Search
Trial Profile

Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alvespimycin (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Sponsors Kosan Biosciences

    • Most Recent Events

    • 28 Oct 2008 Status changed from planning to discontinued, as reported by ClinicalTrials.gov.
    • 23 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780000).
    • 28 Feb 2008 Kosan have reported that this trial will not be continued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top